Cancer immunotherapy has shifted the paradigm for the treatment of cancer; these therapies aim to improve antitumour immune responses with fewer off-target effects than chemotherapies and other agents that directly kill cancer cells [1] [2] [3] . In cancer immunotherapy, agents are used to activate or boost the activation of the immune system to attack cancer cells through natural mechanisms, many of which are evaded during disease progression [1] [2] [3] . Thus, immunotherapy is recognized as a promising strategy to treat, and even cure, certain types of cancer.
. In cancer immunotherapy, agents are used to activate or boost the activation of the immune system to attack cancer cells through natural mechanisms, many of which are evaded during disease progression [1] [2] [3] . Thus, immunotherapy is recognized as a promising strategy to treat, and even cure, certain types of cancer.
The first marketed immunotherapies for cancer were recombinant versions of the cytokine interferon-α (IFNα), which were approved by the US Food and Drug Administration (FDA) in 1986 for hairy cell leukaemia 1 (Table 1) . Some patients who were treated in these early clinical trials experienced partial remission, but IFNα was quickly replaced by purine analogues as a frontline therapy for hairy cell leukaemia because of the short therapeutic duration of IFNα 2 . Shortly thereafter, recombinant interleukin-2 (IL-2) was investigated as an immunotherapy for cancer and was approved by the FDA for metastatic renal cancer in 1992 and for metastatic melanoma in 1998 (ref. ). IL-2 therapy was initially met with great enthusiasm because its use resulted in durable complete responses in some patients 4 . However, high doses were required because of the short half-life of IL-2, which led to serious adverse effects including cytokine release syndrome and vascular leak syndrome, among others [5] [6] [7] . Although the early clinical investigations of these therapies were promising, progress in the field of cancer immunotherapy stalled in the 2000s owing in large part to the failure of many vaccine clinical trials 8 .
Following nearly a decade of relatively unsuccessful vaccine trials, the first successful therapeutic cancer vaccine, sipuleucel-T (an autologous dendritic cell therapy), was approved for prostate cancer in 2010, but its clinical translation was hampered by production complexities and other issues 9, 10 . Shortly thereafter, the pioneering checkpoint inhibitor ipilimumab, a monoclonal antibody (mAb) that targets cytotoxic T lymphocyte antigen 4 (CTLA4), was approved for advanced melanoma in 2011 (ref.
11
). Over the past several years, novel immunotherapies -including other checkpoint inhibitor mAbs that target programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1) 12 , as well as the first chimeric antigen receptor (CAR) T cell therapies [13] [14] [15] [16] have been developed and approved for clinical use. The advent of ipilimumab and CAR T cell therapies was a turning point in cancer immunotherapy, as highlighted by Science as the breakthrough of the year in 2013 (ref.
17
).
There are now over a dozen immunotherapies approved for cancer treatment (Table 1) , and many more are in clinical trials. These immunotherapies fall into several classes, including checkpoint inhibitors, lymphocyteactivating cytokines, CAR T cells and other cellular therapies, agonistic antibodies against co-stimulatory receptors, cancer vaccines, oncolytic viruses and bispecific antibodies.
Despite these major advances, the clinical use of immunotherapies faces several challenges related to both efficacy and safety. With regard to efficacy, Cytokine release syndrome rapid release of cytokines leading to adverse symptoms such as increased heartbeat, nausea and low blood pressure.
only subsets of patients respond to immunotherapies, making it difficult to predict patient responses 18 . Furthermore, there is great interest in developing patient-specific immunotherapies based on biomarker expression on cancer cells and in evaluating combination treatment strategies to improve response rates [19] [20] [21] . Lastly, most immunotherapies were originally evaluated in haematological cancers owing to the delivery barriers faced by solid tumours, such as their compact tumour microenvironments. Recently, several immunotherapies, including activating cytokines and mAbs for checkpoint blockade, have been approved by the FDA for solid tumour therapy 22 . Of note, CAR T cell therapies have not yet been approved by the FDA for solid tumours, but researchers are developing CAR T cells that have high specificity towards cells in solid tumours 23, 24 . With regard to safety, immunotherapy can induce autoimmune side effects in some patients, leading to attacks on healthy tissues. As observed with IL-2 therapy, many immunotherapies cause cytokine release syndrome and vascular leak syndrome, which lead to severe hypotension, fever, renal dysfunction and other adverse effects that are potentially lethal 4, 25, 26 . Novel approaches to administering cancer immunotherapy in a safer, more controlled manner could extend the curative potential of these therapeutic agents to a broader range of patients and could also reduce toxicities. In particular, improved delivery technologies could increase the accumulation of immunotherapies within diseased tissues, enable more effective targeting of the desired tumour and/or immune cells and reduce offtarget adverse effects. Research is ongoing to develop novel delivery platforms for immunotherapies, including nanoparticles, implants, scaffolds, biomaterials Increases production of cytokines when topically applied.
Vascular leak syndrome
Increased vascular permeability that causes fluids from capillary vessels to enter tissues, which can lead to organ damage.
Dendritic cell
a type of antigen-presenting cell whose main function is to present antigens to T cells to modulate the immune system.
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and cell-based platforms 27 ( Table 2) . Several materials, including lipids, polymers and metals, have been utilized to develop delivery technologies, and we refer readers to published articles that specifically discuss the use of such materials 28, 29 . Delivery platforms provide many benefits over the therapeutic agents alone 30, 31 , and throughout this article, we describe precisely how these platforms can be utilized for safer and more effective cancer immunotherapy. First, they can be engineered to protect therapeutic cargo until it is delivered to the targeted cells 32 . Second, delivery systems can enable spatiotemporal control over therapeutics if they are responsive to stimuli such as pH, light or ultrasound, thereby keeping the cargo inactive until it accumulates within target cells [33] [34] [35] . Finally, delivery platforms such as implants have been developed for localized, controlled delivery of drugs, and cell therapies have been developed to minimize toxicities associated with systemic administration [36] [37] [38] . In this Review, we provide a brief overview of several of the main classes of cancer immunotherapy and include their clinical status, advantages and disadvantages. We then focus on novel delivery platforms that have been developed to overcome the challenges faced in the clinical translation of immunotherapies. Our overarching goal throughout this article is to provide insights into how to engineer delivery platforms that have the potential to improve the efficacy and safety of immunotherapies to ultimately improve patient outcomes.
Classes of cancer immunotherapy
This article discusses delivery systems for immunotherapies that fit into one or more of the following five classes: checkpoint inhibitors, lymphocyte-promoting cytokines, engineered T cells such as CAR T and T cell receptor (TCR) T cells, agonistic antibodies against co-stimulatory receptors, and cancer vaccines. Importantly, there are other emerging approaches to immunotherapy such as oncolytic viruses and bispecific antibodies that are not discussed in detail here (Table 1) ; for these topics, readers are referred to other published review articles 39, 40 .
In this section, we provide a brief overview of each of these five classes and highlight limitations that could potentially be addressed through the development of advanced delivery technologies.
Checkpoint inhibitors.
Checkpoint inhibitors are the most thoroughly investigated class of immunotherapy to date. The two most common checkpoint inhibition strategies are PD-1/PD-L1 blockade and CTLA4 inhibition. Other checkpoint inhibitors in earlier phases of clinical development are reviewed in detail elsewhere [41] [42] [43] . 41 . When T cells become activated -for example, in response to inflammationthey express PD-1, which enables them to recognize abnormal and cancerous cells 44, 45 . To evade recognition and elimination by T cells, tumour cells express PD-L1, which binds to PD-1 on T cells to render those cells inactive 44, 46 . Therefore, blocking this interaction with mAbs that target either PD-1 or PD-L1 enables T cell-mediated tumour cell death. Another immune checkpoint, CTLA4, is a co-inhibitory molecule that regulates the extent of T cell activation. Interactions between CTLA4 and its ligands -CD80 and CD86 -inhibit T cell activity and thus promote tumour progression 42 . By blocking the interaction between CTLA4 and these ligands, T cells remain active and can recognize and kill tumour cells. It is important to note, however, that the precise cellular mechanisms underlying CTLA4 blockade remain under investigation, and each of the CTLA4-targeted antibodies has different properties 47 . For example, some anti-CTLA4 antibodies may both deplete regulatory T cells and inhibit checkpoint functionality 48, 49 .
The clinical impact of PD-1, PD-L1 or CTLA4 checkpoint blockade strategies has grown considerably over the past few years. So far, five PD-1 or PD-L1 inhibitors and one CTLA4 inhibitor have been approved to treat various cancers based on improvements in overall survival compared with traditional chemotherapies 50 (Table 1) , and many trials involving checkpoint inhibitors in combination with chemotherapy or other targeted agents (>700 trials) are ongoing. Nevertheless, their use has several key limitations. As mentioned above, systemically administered checkpoint inhibitors can have severe side effects in numerous organs 26, [51] [52] [53] . Second, many patients do not respond to treatment with checkpoint inhibitors. Factors underlying responsiveness to checkpoint inhibitors are being intensely studied 18 and may include low numbers of tumour-infiltrating T cells, deregulation of checkpoints in both tumour cells and T cells, and adapted resistance to checkpoint inhibition [54] [55] [56] . Additionally, different tumour microenvironments have distinct mechanisms of immunosuppression that require novel approaches for successful treatments 57 . These limitations, and others, can be addressed by advanced delivery technologies, as described below.
Cytokines. Cytokines were the first class of immunotherapy to be introduced into the clinic, with the approval of recombinant IFNα therapies in 1986 (ref.
2 ). This strategy differs from checkpoint blockade approaches because injected cytokines directly stimulate the growth and activity of immune cells. The three main types of cytokine that have been pursued for immunotherapy are interferons, interleukins and granulocyte-macrophage colony-stimulating factor (GM-CSF) 4 . Interferons are normally produced by immune cells in response to microbial pathogens and elicit immune responses by inducing the maturation of numerous immune cells including macrophages, natural killer (NK) cells, lymphocytes and dendritic cells [58] [59] [60] [61] . Interferon activation of immune cells can also inhibit angiogenesis in the extracellular tumour space 4, 59, 62 . Interleukins stimulate the activity and growth of CD4 + T cells and CD8
+ T cells [63] [64] [65] [66] . Finally, GM-CSF improves immune responses through two mechanisms: promoting T cell homeostasis, which improves T cell survival, and supporting dendritic cell differentiation so that these cells express tumourspecific antigens 67 . Both granulocyte colony-stimulating factor (G-CSF) and GM-CSF have been used to augment and accelerate granulocyte recovery after chemotherapy, but GM-CSF may be more pro-inflammatory than G-CSF [67] [68] [69] . In addition to these widely studied cytokines, researchers are also investigating agonists that activate immune cells via intracellular mechanisms. For example, TGFβ receptor type 1 (TGFβR1) inhibitors, such as SD-208, restore T cell function and improve immune responses 70 . Additionally, small-molecule agonists of TLR7/TLR8 directly activate antigen-presenting cells (APCs) to promote antitumour activity, and stimulator of interferon genes (STING) agonists have been used to induce pro-inflammatory cytokine production and other type I interferon responses 71, 72 . Three immune-activating recombinant cytokines are approved for cancer immunotherapy (Table 1) , and several more, including IL-17 and IL-15 (refs 73,74 ), are in clinical development. However, owing to their somewhat short half-life, treatments generally consist of high-dose bolus injections that cause vascular leakage and cytokine release syndrome 4 . Furthermore, cytokine therapy can promote the survival of regulatory T cells and induce death in stimulated T cells, ultimately causing an autoimmune attack against healthy tissues 25 . The use of IL-15 and IL-21 may have some advantages over IL-2 in these respects 75, 76 . Current research and clinical trials are investigating their use in combination treatment strategies with two or more cytokines (for example, interleukins and interferons together) or with checkpoint inhibitors or chemotherapies to reduce the adverse effects of high treatment dosages that are required for the therapies if used independently 59 .
Engineered T cells: chimeric antigen receptor T and T cell receptor T cells.
Recently, CAR T cells have gained attention from their clinical successes and expedited FDA approvals. In the CAR T cell approach, T cells are collected from patient blood and are then genetically engineered to express CARs that are specific for an antigen present on tumour cells. These engineered T cells are then re-administered to the same patient. Upon injection, CAR T cells recognize the targeted antigen on tumour cells to induce tumour cell death 77 . Unlike other treatment options, CAR T cells are typically a onetime therapy, and the cells can retain their activity for over a decade after injection 13, 78 . Many patients achieve remission and prolonged survival, but the long-term effects of CAR T cell therapy remain under investigation 14, 79 . Furthermore, the production of CAR T cells is expensive, technically complex, and time intensive, all of which are major considerations for the widespread implementation of CAR T cell therapies 80 . In addition, www.nature.com/nrd in some circumstances (particularly solid tumours with harsh microenvironments), the infused cells do not persist, so combination therapies and novel drug delivery systems are needed to improve T cell survival. The initial target for CAR T cells was CD19 because this molecule is frequently expressed on B cell leukaemias and lymphomas. CD19 expression in normal tissues is confined to the B cell lineage, so any on-target, off-tumour activity would be limited by b cell aplasia, a side effect that can be mitigated with immunoglobulin replacement therapy 81 . Currently, two CD19-targeting CAR T cell therapies are approved for clinical use by the FDA: axicabtagene ciloleucel for diffuse large B cell lymphoma and tisagenlecleucel for acute lymphoblastic leukaemia and diffuse large B cell lymphoma 82, 83 . The clinical success of CD19 CAR T cells has encouraged many efforts to engineer CAR T cells that target different antigens, or a combination of several antigens, for a more generalizable approach to cancer therapy 77, [84] [85] [86] [87] [88] . However, these efforts are met with two key challenges. First, both CAR T and TCR T cells can cause cytokine release syndrome and neurotoxicity 89, 90 . The second issue is how to enable these engineered cells to have efficacy in solid tumours 85, 91, 92 . Thus far, in the few solid tumours that have been successfully treated with CAR T cells, such as EGFRvIII-expressing glioblastoma 85 , the target antigen is expressed at vastly higher levels on tumour cells compared with normal cells.
TCR T cells are engineered cells that are being tested in clinical trials for both haematological and solid cancers. TCRs respond to tumour-associated intracellular antigens presented by major histocompatibility complexes (MHCs) 93 . The choice of antigenic target for TCR T cells can be shared antigens, such as cancer-testis antigens, or patient-specific neoantigens that result from tumour mutations 94 . Unlike MHC-independent CAR T cells, TCR T cells must be MHC-matched with the patient. Preclinical investigations of TCR T cells indicate that the specificity of the infused T cells is of paramount importance 95 . Furthermore, the results from initial trials with TCR T cells suggest that toxicity from T cells that use high-affinity TCRs is difficult to predict 96 . Researchers are developing novel delivery technologies to overcome the toxicities associated with both CAR T cells and TCR T cells and improve their applicability for solid tumours, as described below.
Co-stimulatory receptor agonists. Agonistic antibodies are designed to specifically bind to receptors on the surface of T cells and trigger intracellular signalling pathways that induce T cell growth, survival and effector function against tumour cells 97 . The most commonly targeted T cell receptors are co-stimulatory receptors (namely CD28) and several members of the tumour necrosis factor receptor (TNFR) family, such as 4-1BB (also known as TNFRSF9 or CD137), OX40 (also known as TNFRSF4) and glucocorticoid-induced TNFR-related protein (GITR; also known as TNFRSF18), that are expressed on the surface of APCs 98 . Ligand binding to these co-stimulatory receptors triggers intracellular cell signalling that promotes T cell growth and anticancer activity 25, 99 . Ligand binding to the TNFR family members likely acts through the NF-κB, JNK and PI3K-PKB (also known as AKT) pathways 98 , which are implicated in cell survival, proliferation and effector function.
Agonistic antibodies are at an earlier stage of development than other classes of immunotherapy discussed in this Review, as there are none approved by the FDA. Nevertheless, several agonistic antibodies that target different receptors have reached clinical trials. At present, the furthest advanced candidates are in phase II trials: two agonistic antibodies that target 4-1BB (utomilumab and urelumab 100, 101 ) and several that target OX40 (PF-04518600, BMS-986178 and INCAGN-01949, among others) 102 . Thus far, studies have shown that agonistic antibodies have dose-limiting toxicities similar to those for cytokines, as they can induce activity in undesired subtypes of immune cells and immune activity towards healthy cells 98 . Furthermore, certain agonistic antibodies induce regulatory T cell activity 103 . Ongoing clinical trials are evaluating the toxicities associated with specific dosages and administration schedules, and delivery platforms are being developed to address these concerns. For example, anti-4-1BB antibodies anchored to liposomal nanoparticles have more intratumoural accumulation and lower toxicities than freely delivered antibodies in both subcutaneous and intravenous lung metastasis mouse models 104 . Future studies should specifically address how delivery platforms for agonistic antibodies can enable control over exposure duration while still inducing multivalent T cell activation.
Cancer vaccines. Types of cancer vaccine include tumour cell lysate, dendritic cells, nucleic acids (such as mRNA) or neo-antigens 105 . For brevity, here we discuss the latter three, and we refer readers to published review articles for information on tumour cell lysatederived vaccines 106, 107 . Dendritic cell vaccines are the most commonly studied class of cell-based cancer vaccine 55 . Dendritic cell vaccines are made from dendritic cells collected from patients that are engineered to express tumour-associated antigens and thus directly activate T cells to attack cancer cells 55 . As noted above, one dendritic cell vaccine, sipuleucel-T, was approved to treat prostate cancer in 2010 on the basis of its ability to prolong overall survival 9, 108 . Although other dendritic cell-based vaccines have demonstrated high safety profiles, they have failed in clinical trials owing to lack of efficacy 8 . It is anticipated that efficacy can be improved by identifying particular subsets of dendritic cells that express high levels of targeted antigens 55 and by improving delivery to the relevant lymph nodes 55, 109, 110 . Nucleic acid therapeutics, such as DNA-based or RNA-based vaccines, have emerged as promising alternatives to conventional vaccines and rely on the intracellular delivery of exogenous nucleic acids into target cells 111 . In these technologies, DNA or mRNA is taken up by APCs and translated to induce antigen expression. The targeted antigens are presented to T cells to induce their activation against tumour cells that express the antigen of interest 111 . DNA vaccines have been tested in a number of clinical trials, but they are often unsuccessful because of nuclear delivery barriers and immunogenicity [112] [113] [114] . Alternatively, mRNA-based NAtuRe Reviews | DRUg DiSCoveRY cancer vaccines have been developed to directly induce APCs to express antigens that are implicated in immune recognition 111 . Because mRNA is a naturally occurring molecule, it can be easily produced, and its half-life can be extended with modifications. mRNA is also noninfectious and does not integrate into the genome as many DNA vaccines do 111, 115 . However, mRNA is quickly degraded by nucleases and cannot easily be internalized by cells, so it requires the use of transfection agents or delivery platforms to mediate intracellular delivery 111, 116 . Thus, nucleic acid vaccines can greatly benefit from delivery technologies that improve intracellular (for mRNA) or intranuclear (for DNA) delivery.
Neoantigen vaccines are being investigated as cancer immunotherapies for their ability to boost the immune response to cancer cells 117, 118 . Neoantigens are tumourspecific antigens that arise from somatic DNA alterations in cancer cells, and one main benefit of using neoantigens is that they are present only in cancer cells, so off-target adverse effects are virtually eliminated 117 . Furthermore, these vaccines can encompass an unlimited number of neoantigens, which is ideal for treating heterogeneous cancers. Delivery platforms can improve upon the success of both mRNA and neoantigen vaccines by improving the stability of the encapsulated molecules and by harbouring several mRNA sequences or neoantigens within one platform for a comprehensive approach to treat heterogeneous cancers, as described below 119, 120 .
Need for novel delivery technologies
The five classes of immunotherapy described here each face delivery challenges, some of which are shared and others of which are class-specific. Checkpoint inhibitors, cytokines and agonistic antibodies have similar delivery challenges. The success of these therapies relies on their interaction with the targeted protein. A major limitation of their use is that they produce substantial autoimmunity, leading to adverse effects that limit the allowable administered doses 26 . For this reason, a central goal in the development of delivery technologies for these therapies is to enable targeted and controlled release so that the therapies are primarily active in the desired cell types, which should minimize off-target effects.
The microenvironment in many solid tumours is a challenge to the broad implementation of all the immunotherapy classes discussed here 121 . For example, the microenvironment of solid tumours can be categorized as either immunologically 'hot' (high immunogenicity) or 'cold' (low immunogenicity), which have either high or low levels of cytotoxic lymphocyte infiltration within the tumour space, respectively 121 . This key difference in the composition of the microenvironment suggests that tumours with high immunogenicity exhibit stronger responses to checkpoint inhibitors than do tumours with low immunogenicity 121 . Delivery technologies can therefore be exploited to modulate immunogenicity in cold tumours. In addition, because delivery platforms can also reduce the systemic toxicity of immunotherapies by limiting drug exposure to particular tissues 25, 122 , they can be used to deliver combinations of therapeutics that would otherwise be too toxic to administer to patients.
In an elegant example of this combination effect, liposomal nanoparticles were complexed with a PD-L1 trap plasmid (to block PD-L1 signalling) and cationic protamines to form lipid-protamine-DNA (LPD) nanoparticles that are targeted to tumour tissue using aminoethyl anisamide ligands 122 . Mice bearing orthotopic colorectal tumours were intravenously injected with both the LPD nanoparticles and the chemotherapy drug oxaliplatin, which has been shown to activate dendritic cells and induce immune activity in tumours in addition to its DNA-damaging effects in tumour cells 122 . Thus, oxaliplatin may cause immunologically cold tumours to become hot and therefore susceptible to LPD therapy. The tumour-targeted LPD nanoparticles and oxaliplatin worked synergistically to inhibit tumour growth and exhibited reduced toxicity compared with that seen in mice treated with PD-L1 antibodies and oxaliplatin with no nanoparticle carrier 122 . This demonstrates that nanoparticles can potentially enable combination treatment strategies to make tumours with low immunogenicity susceptible to immunotherapy.
In addition to enabling combination treatment strategies, nanomedicines can be designed to respond to the tumour microenvironment and increase penetration at those sites 123 . In an interesting example of this, 100 nm nanoparticles composed of gelatin were coated with 10 nm quantum dots that were released upon exposure to matrix metalloproteinases (MMPs), which are often present in tumour microenvironments 123 . In this study, the nanoparticles were intratumourally injected into fibrosarcomas in a dorsal skin-fold window chamber model, and the quantum dots that were delivered on nanoparticles penetrated the tumour tissue substantially more than nonreactive quantum dots alone 123 . Thus, by replacing the quantum dots to generate therapeutic-loaded nanoparticles, this unique design could be exploited to deliver therapeutics through solid tumours with both high and low immunogenicity, the latter of which would otherwise not be susceptible to immunotherapy.
Delivery systems for immunotherapies that require intracellular delivery, such as some small-molecule agonists and genetic vaccines, must overcome extracellular and intracellular barriers with minimal systemic toxicity. Nucleic acids are negatively charged, and so they require a secondary agent, typically lipid or polymer transfection reagents, in order to be taken up by cells. Furthermore, DNA vaccines need to pass through both the cellular and nuclear membranes to be transcribed in the nucleus 113 . By contrast, mRNA requires penetration into only the cell cytosol for protein translation, but without modifications or delivery platforms, mRNA is quickly degraded by nucleases 120 . Delivery technologies for these vaccines protect nucleic acids from degradation and enable intracellular delivery without toxic transfection reagents. Nanoparticle delivery systems in particular must escape from endosomes inside cells to enter the cytoplasm and avoid exocytosis from late endosomes. In a recent study, 70% of the small interfering RNA (siRNA) molecules encapsulated within lipid nanoparticles underwent exocytosis 124 . To disrupt endosomes and enable cytosolic delivery, ionizable and bioreducible materials can be specifically designed to degrade inside cells and facilitate www.nature.com/nrd the escape of nucleic acids from endosomes into the cytoplasm 125 . Similar to nucleic acids, the use of intracellular agonists, such as those that target either TLR7/TLR8 or STING, is often limited to administration via intratumoural injection, as intravenous administration can lead to systemic toxicity 126 . Thus, delivery technologies for these innate immune system agonists and other immunotherapies that require intracellular delivery should aim to encapsulate and protect the therapeutic cargo until it can be released into the cytosol of target cells. Below, we describe a range of delivery technologies that have recently been developed to improve the safety and efficacy of cancer immunotherapies, and we discuss the anticipated clinical impact of these delivery systems 9, 23, 87, [127] [128] [129] [130] .
Delivery strategies for immunotherapy
For decades, it has been thought that selective nanomedicine delivery to tumours could exploit an enhanced permeability and retention (EPR) effect -characterized by the greater permeability of tumour vessels than normal vessels to macromolecules and the retention of macromolecules in tumours owing to poor lymphatic clearance [131] [132] [133] (fIg. 1a) . Although the EPR effect is pronounced in preclinical models of solid tumours that exhibit leaky vasculature and is also observed in humans, the potential to harness it therapeutically in patients with cancer remains unclear, and most nanotherapeutics investigated in clinical trials have not demonstrated substantial benefits over conventional chemotherapy 134, 135 . A meta-analysis of 117 studies of nanomedicine delivery, some of which relied on either the EPR effect or active targeting of cancer cells, showed that only 0.7% (median) of administered nanoparticles reach tumours 136 . Magnetic resonance imaging (MRI) or positron emission tomography (PET) studies to assess the role of the EPR effect in tumours revealed high variability of solid tumour permeability both between patients and between tumours in individual patients 137, 138 . These findings demonstrate the importance of understanding the physical microenvironment of tumours and their permeability in order to optimally engineer delivery systems for tumour penetration and uptake.
Importantly, different routes of administration can influence the therapeutic efficacy of delivery technologies. For example, local delivery using intratumoural injections or implantable scaffolds may result in higher accumulation of drugs in tumours, but it may not be feasible for tumours that are not easily accessible. Thus, the route of administration is an important consideration when evaluating delivery technologies for immunotherapies for specific types of cancer. A simple approach to improve biodistribution is to conjugate polyethylene glycol (PEG) to therapeutic agents, such as cytokines, to improve half-life and stability; this technique is being investigated in clinical trials 4, 139 . However, PEGylation is not selective for tumour tissue and is still limited by offtarget effects. As an alternative way to selectively deliver drugs (typically cytotoxic therapies) to tumours, nanoparticles have been designed with the goal of directly 1b) . Although active targeting improves the retention of nanoparticles in tumours, it has not substantially improved biodistribution and localization of the nanoparticles within the tumour 142 . Beyond these approaches that rely on systemic administration, technologies for local delivery, such as injectable hydrogels, implantable biomaterials and microneedles, are also being explored 37, 143, 144 . Additionally, delivery technologies are being developed to directly target immune cells in the bloodstream (fIg. 1c) . In this regard, nanoscale delivery systems have been designed for a range of immunotherapy applications, including the delivery of drugs directly to tumour-infiltrating immune cells in the bloodstream, mRNA cancer vaccine technologies that target dendritic cells in the spleen and nanoscale conjugates that accumulate immunotherapeutics within lymph nodes and the extracellular matrix. Below, we describe novel delivery platforms that utilize each of these strategies, and others, for improving immunotherapy.
Nanoparticles and conjugates Nanoparticles targeting T cells in blood. Nanoparticlebased approaches have recently been designed to target immunotherapeutic agents directly to T cells 145 . Immune cells such as T cells can migrate actively into tumours, leveraging chemokine gradients to traffic to sites of inflammation within tumours 146 . In contrast to delivering cytotoxic agents to tumour cells, which requires nanoparticles to kill most or all of the target cells to be effective, lower concentrations of immunestimulating drugs can be used to stimulate or amplify a T cell response. In one approach, the FDA-approved polymers poly(lactic-co-glycolic acid) (PLGA) and PEG were used to synthesize nanoparticles encapsulating either SD-208, a TGFβR1 inhibitor, to restore T cell function, or a TLR7/TLR8 agonist to recruit lymphocytes to non-inflamed tumours 145 . Antibody fragments were conjugated to the surface of nanoparticles via thiolmaleimide click chemistry, such that the nanoparticles bound PD-1-expressing T cells in the circulation and in tumours 145 . Targeting TGFβR1 inhibitors to T cells using nanoparticles extended survival in a mouse model of colorectal cancer compared with free drugs at similar dosages, and targeted delivery of the TLR7/TLR8 agonist increased the proportion of tumour-infiltrating CD8 + T cells and sensitized tumours to anti-PD-1 therapy 145 . Collectively, targeting the delivery of nanoparticle-based immunotherapies to tumour-infiltrating immune cells in blood, rather than targeting tumour cells directly, is a potentially attractive means to improve immunotherapeutic localization in tumours and to stimulate an antitumour response.
Vascular receptor-mediated adhesion of drugs to immune cells. Liposome-based drug delivery systems have been developed to bind immune cells in the circulation by leveraging receptor-ligand interactions based on those between immune cells and the inflamed endothelium 147, 148 . In two examples, liposomes were functionalized with the vascular adhesion receptor E-selectin alone or together with the immune cytokine TRAIL (also known as TNFSF10) to selectively induce tumour cell apoptosis [147] [148] [149] . Ligands for E-selectin are expressed on both circulating tumour cells and immune cells, and TRAIL engages death receptors on the surface of cancer cells to induce apoptosis. In vivo, the E-selectin-TRAIL nanoparticles bound to immune cells in blood with negligible side effects 147 , and the half-life of TRAIL was substantially increased because it was tethered to the surface of immune cells 148 . These nanoparticle-coated immune cells were initially utilized to target and kill circulating tumour cells in the bloodstream to reduce metastatic tumour formation, and they killed most of these cells within 2 hours 147 . This approach also reduced the overall tumour burden in a murine model of prostate cancer, indicating that tumour-infiltrating immune cells likely migrate into solid tumours to deliver immune cytokines and induce antitumour responses 148 . Collectively, these results indicate that receptor-ligand interactions that occur within the vasculature can be exploited to deliver immune-based drugs to endogenous immune cells, which can then migrate into the tumour to deliver therapeutics.
Nanoparticles for mRNA cancer vaccines. As noted above, mRNA vaccines are promising platforms for cancer immunotherapy 111 . However, their application has been limited by their instability and inefficient in vivo mRNA delivery 150 . The challenges to efficient in vivo delivery are numerous. mRNA vaccines must avoid degradation by endonucleases in physiological fluids and in the extracellular space and evade renal clearance via glomerular filtration. Furthermore, they need to diffuse through the compact extracellular matrix to reach the target cells 151 and then be taken up and escape the endosome to release mRNA into the cytosol, where translation occurs [152] [153] [154] (fIg. 2) . Recently, delivery systems have been designed to overcome these biological barriers to in vivo mRNA delivery, as described below 155, 156 . Two methods of improving mRNA delivery utilize viral or lipid-based formulations. Viral delivery systems, including lentiviruses, adeno-associated viruses and the Sendai virus, are capable of systemically delivering nucleic acids, including mRNA 157, 158 . However, the use of viral delivery systems is limited, in part owing to the induction of unwanted immune responses 159 . As an alternative to viral delivery, nonviral systems comprising lipids and lipid-like materials have been efficacious in preclinical animal models as well as in initial clinical studies 155, 156 (fIg. 3a) . In a recent study, a lipid-based nanoparticle mRNA vaccine was designed to target dendritic cells in vivo without the need for antibodies or adhesion ligands 156 . This platform comprises several off-the-shelf lipids that were used in the earliest nucleic acid delivery systems, including the cationic lipids DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium-propane) and DOTAP (1,2-dioleoyl-3-trimethylammonium-propane), as well as the zwitterionic lipid DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), which form complexes with anionic mRNA 160 (fIg. 3b) . Rather than incorporating antibodies or ligands, alterations of the RNA-to-lipid ratio -and thus the surface charge of the nanoparticle formulation -improved intravenous mRNA delivery These vectors need to prevent degradation of the mRNA by serum endonucleases and evade macrophage detection (which could be achieved by chemical modifications and encapsulation of nucleic acids). They also need to avoid renal clearance from the blood and prevent nonspecific interactions (by using polyethylene glycol (PEG) or through particle design). Moreover, these vectors need to extravasate from the bloodstream to reach dendritic cells in target tissues and mediate dendritic cell entry and endosomal escape. Once mRNA is in the cytosol, it is translated into the antigenic peptide, which is then processed into smaller peptide epitopes that bind to the major histocompatibility complex (MHC) class I or class II molecules. The MHCs are trafficked to the cell surface, where they present their antigenic epitopes to either CD8 + (cytotoxic) T cells or CD4 + (helper) T cells, leading to a cytotoxic T cell response or an antigen-specific antibody response, respectively. The order of the steps of mRNA entry and processing is shown by sequential numbering. Figure adapted from 
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to dendritic cell-containing compartments in the spleen and lymphoid tissues of mice 156 . Interestingly, studies using nanoparticles containing mRNA that encodes a fluorescent protein showed that overall biodistribution in mice was more dependent on nanoparticle charge than on the lipid material used 156 . The lead nanoparticle candidate enabled dendritic cells to translate mRNA and subsequently express tumour antigens, present them to T cells and mediate potent rejection of tumours in murine models of melanoma and lung and colorectal cancer 156 . Of note, this platform is in clinical trials for melanoma therapy and has shown promising immune responses in patients 156, 161 .
Ionizable lipid nanoparticles for in vivo mRNA delivery. Although approaches utilizing cationic lipids have promising efficacy, they are both toxic and immunogenic. Intravenously injected cationic liposomes can cause liver damage 162 , destabilize the plasma membrane of non-targeted cells 163 and induce inflammation 164 . Additionally, the positive charge of these lipids can be negated via adsorption of anionic serum proteins to liposomes, thereby reducing intracellular nucleic acid delivery 163 . As a means to overcome the challenges faced in using cationic lipids for mRNA-based immunotherapies, ionizable lipid-like materials have been designed to reduce the toxic side effects of cationic lipids while retaining their transfection characteristics 155, 165 ( fIg. 3c) . Ionizable lipids are positively charged at low pH, which enables complexation with mRNA in nanoparticles in acidic buffers, and they are neutral at physiological pH, which reduces toxicity compared with cationic lipids 150, 165 . The positive charge from lipids also increases cellular uptake via endocytosis and subsequent nanoparticle deposition into endosomes, which reduce their pH (from ~6.8 to 4.5) as they transition into lysosomes 166 . Thus, it is believed that the positive charge of these ionizable lipids enables electrostatic interaction and fusion with the negatively charged endosomal membranes, leading to destabilization of the bilayer and subsequent release of nucleic acids into the cytosol. However, the precise mechanisms of endosomal release remain under investigation [167] [168] [169] . In one critical study, a lipid nanoparticle formulation composed of an ionizable lipid, a phospholipid, cholesterol and a PEG-lipid conjugate was engineered for the delivery of mRNA vaccines to induce a cytotoxic T cell response 155 (fIg. 3a) . Upon subcutaneous administration, the nanoparticles successfully transfected a range of immune cells, including dendritic cells, macrophages and neutrophils, and accumulated in lymph nodes 155 . This technology was also evaluated in a murine model of melanoma, in which a single immunization with nanoparticles induced strong CD8 + T cell proliferation and functionality, as mice treated with these nanoparticles had extended survival compared with controls 155 . Furthermore, treatment of mice with nanoparticles that contained mRNA encoding the tumour antigens gp100 (also known as PMEL) and TRP2 (also known as DCT) resulted in overall tumour shrinkage and extended survival in an aggressive melanoma tumour model 155 . This study demonstrates the capacity of ionizable lipid nanoparticles to improve the delivery of mRNA vaccines and induce powerful immune responses.
Polymeric systems such as dendrimers have also been developed for mRNA vaccine delivery 170, 171 . These systems have been utilized to deliver large therapeutic payloads such as replicon mRNA, which can substantially amplify the production of encoded protein. This was demonstrated in various applications including vaccines for H1N1 influenza, Toxoplasma gondii and Ebola virus 170, 171 . These technologies should now be evaluated for their capacity to deliver replicon mRNA for the sustained production of tumour antigens.
Bioinspired molecular conjugate subunit vaccines.
Subunit vaccines contain purified peptides, proteins or polysaccharides in combination with molecular adjuvants that are designed to boost the immune response. These vaccines are easier to manufacture and potentially safer than live vaccines. However, subunit vaccines typically elicit weaker immune responses than live pathogens in part because of inefficient antigen and adjuvant delivery to secondary lymphoid organs, where immune responses are coordinated 30, 172 . Improving the adjuvant effect of subunit vaccines is a promising means to improve the immune response in these systems, and this strategy has been previously reviewed in detail 173 . Molecular conjugates that target dendritic cells in the draining lymph nodes are another attractive approach, but antibody-antigen conjugates designed for such purposes have been shown to drain into the bloodstream, thus reducing accumulation in lymph nodes 174 (fIg. 3d) .
In an alternative strategy, vaccine conjugates were designed to increase the accumulation of subunit vaccines in draining lymph nodes 175 . These amphiphilic vaccines consist of an antigen or adjuvant conjugated to an albumin-binding lipophilic tail and linked using a functionalized PEG block 175 (fIg. 3d) . Compared with the free compounds, more of these conjugates accumulated in the lymph nodes, and drainage into the bloodstream was reduced. This accumulation induced a 30-fold increase in T cell priming, improved antitumour efficacy in a murine model of melanoma and reduced systemic toxicity 175 . Vaccine conjugates have also been incorporated into a combinatorial immunotherapy approach that includes a tumour antigen-targeting antibody, an engineered version of IL-2 with an extended half-life and an anti-PD-1 mAb 176 . This approach recruited numerous innate and adaptive immune cells -which even attacked tumour proteins not directly targeted by the cocktail itself -to eradicate large tumour burdens in genetically engineered mouse (GEM) models of melanoma or syngeneic tumour models 176 . Given both the improved targeting to lymph nodes and the simple conjugation of this approach, this platform can be applied to a broad range of subunit vaccines to increase their potency and reduce off-target toxicity.
Matrix-binding checkpoint inhibitor conjugates.
As a means to avoid the immune side effects associated with systemic administration of checkpoint inhibitors, matrix-binding molecular conjugates have been designed to be retained intratumourally and peritumourally and to reduce systemic drug exposure 177 . In one example, NAtuRe Reviews | DRUg DiSCoveRY checkpoint inhibitors were bound to a peptide derived from placental growth factor 2 (PLGF2), which has an exceptionally high affinity for multiple matrix proteins, using a water-soluble, amine-to-sulfhydryl crosslinker 177 ( fIg. 3e) . Following peritumoural administration, these conjugates remained more localized in the extracellular matrix near tumour tissue than unmodified inhibitors. This localization delayed tumour growth and prolonged survival in GEM models of melanoma and breast cancer 177 . Furthermore, these conjugates induced systemic antitumour immunity and reduced treatment-related toxicities that are commonly associated with systemic administration of checkpoint inhibitors. Importantly, engineering matrix-binding conjugates is scalable and, by means of intraperitoneal or peritumoural injection, enables local delivery of checkpoint inhibitors to additional tumour sites in the body that cannot easily be reached by systemic administration.
Biomaterials: localized immunotherapy
Controlled release technologies. Although immunomodulatory antibodies can induce robust antitumour immune responses, systemic delivery of these agents can induce cytokine release syndrome and abnormal liver function 178 . To minimize off-tissue effects, delivery systems have been designed for local and sustained release in vivo. Early controlled release systems were composed of mineral oils and polymeric microspheres and were generally used for the local delivery of immunomodulatory antibodies [179] [180] [181] [182] . More recent research has investigated controlled release technologies to reduce these toxicities, as discussed below.
In an interesting platform, Montanide ISA 51, a commercially available mixture of light mineral oils that has been used in immunotherapy clinical trials 179 , was used to prepare a sustained release formulation for local delivery of agonistic anti-CD40 antibodies 181 . Compared with systemic administration of free antibodies, local injection of this controlled release system required lower dosages of antibody to activate T cells and abrogated systemic toxicity. Furthermore, this platform eradicated local and secondary tumours in a mouse model of lymphoma 181 . An expanded study used Montanide ISA 51 to deliver anti-CTLA4 antibodies in a mouse model of colon cancer 180 . Importantly, ongoing clinical trials that study Montanide ISA 51 should provide valuable information on the pharmacokinetics and dosing regimens for specific cancers, as well as its efficacy in combination with adjuvants. Given that Montanide ISA 51 induces inflammation, swelling and granulomas at the injection site in mice 183 , biodegradable polymeric microparticle formulations have also been designed for local and sustained delivery of immunomodulatory antibodies 182 . In one study, a biodegradable polymer, poly(d,l-lactic-co-hydroxymethyl glycolic acid) (PLHMGA), was utilized to slowly release anti-CD40 and anti-CTLA4 antibodies in a mouse model of colon cancer 182 . PLHMGA is a hydrophilic polymer that is characterized by reduced acidification and thereby provides better protection from degradation and sustained release of encapsulated immunotherapeutics relative to other controlled release polymers such as PLGA 182 . Impressively, a local injection of PLHMGA microparticles (approximately 12-15 μm in diameter) enabled the controlled release of antibodies over 30 days, with comparable efficacy to antibodies formulated in incomplete Freund's adjuvant, which is similar in formulation to Montanide ISA 51 (ref.
182
). These polymeric microspheres were designed to be fully resorbed in vivo with lower antibody serum levels, providing a long-lasting immunotherapy delivery system with a decreased risk of adverse systemic effects 182 . Implantable biomaterials to programme dendritic cells in situ. Dendritic cell-based vaccines seek to improve the immune response to cancer by isolating and activating dendritic cells ex vivo and reintroducing them into the patient so they can traffic to lymph nodes and present antigens to naive T cells to subsequently expand and elicit antitumour responses. However, these vaccines require complex modifications of cells in vitro, and most injected cells die upon transplantation 184 . To overcome this, implantable biomaterials, which provide a physical structure to attract and programme dendritic cells for immunotherapy in situ 36, 185 (fIg. 4) , have been used for cancer therapy 144 . In these systems, polymeric scaffolds serve as the drug delivery device, controlling the delivery of bioactive molecules in space and time to recruit dendritic cells and induce their proliferation 36, 186 . Tumour antigens can also be immobilized on these matrices, enabling them to serve as antigen-presenting structures where dendritic cells are recruited, activated, loaded with antigen and released 36, 186 . In one example of an implantable biomaterial, porous poly(lactide-co-glycolide) (PLG) scaffolds were encapsulated with GM-CSF to stimulate dendritic cell recruitment and proliferation. Upon implantation in mice, these scaffolds recruited approximately the same number of dendritic cells as are typically administered using ex vivo based protocols 36, 187 . Unlike a conventional bolus vaccination, the implantable scaffolds created a physical environment in vivo that secreted and presented antigens and stimulatory signals to dendritic cells over the course of 2 weeks 34 . Encapsulation of bioactive molecules (GM-CSF or CpG oligodeoxynucleotides (CpG-ODNs)) in combination with tumour cell lysate antigen immobilization on the scaffold generated specific and protective antitumour immunity upon implantation in vivo, and this induced complete regression of tumours in ~47% of mice in a preclinical melanoma model 36, 186 . Immunostimulatory agents can also be incorporated into these systems, and their release can be tightly controlled. Inflammatory cytokines such as CC-chemokine ligand 20 (CCL20) or FMS-related tyrosine kinase 3 ligand (FLT3L) have been used in scaffolds to alter dendritic cell subset recruitment and activation, which generated antitumour responses in a mouse model of melanoma 188 . Furthermore, numerous sources of tumour lysate, including murine lung carcinoma and rat glioma, have been incorporated into scaffolds as antigens, expanding the therapeutic activity of immunotherapies in model organisms 189, 190 . A human version of this vaccine, termed WDVAX (ClinicalTrials.gov identifier: NCT01753089), is currently being evaluated www.nature.com/nrd in a phase I clinical trial for stage IV melanoma and has been licensed to Novartis for commercial use 191 . However, the use of tumour cell lysates could increase the complexity of clinical translation. Moving forward, platforms should be engineered to incorporate specified antigens or synthetic neoantigens to create personalized vaccines 192 .
Injectable scaffolds for immunotherapy. The scaffoldbased delivery system requires an invasive surgical procedure for implantation, which presents a logistical challenge. In addition to implantable scaffolds, materials including alginate hydrogels, gelatin and mesoporous silica microrods are being designed to create local immunogenic environments that recruit, activate and release immune cells in vivo without the need for surgical implantation 185, [193] [194] [195] [196] . These materials are both highly deformable and self-organizing and thus can be administered via injection.
In one example of this, injectable high-aspect-ratio mesoporous silica rods were designed to spontaneously self-assemble in vivo to form macroporous structures for immune cells 185, 196 (fIg. 4) . Mesoporous silica has been utilized extensively for controlled drug delivery owing to its high pore volume, large surface area, and biocompatibility 197, 198 . Upon injection in mice, silica rods nonspecifically assembled into porous structures that were large enough to host immune cells and also released embedded GM-CSF, CpG-ODNs and tumour antigens 185 . Compared with bolus controls, the silica rod-based vaccine increased the number of cytotoxic T cells and the levels of serum antibodies that result from helper T cell activation and also extended survival in a mouse model of lymphoma 185 . Nanoparticles have also been modified with the cationic polymer polyethyleneimine (PEI) 197, 199 , which can stimulate pro-inflammatory cytokine production 200 , as a means to increase the immunogenicity of neoantigens that target heterogeneous tumour clones 196 . After diffusion of PBS from the pocket, in situ spontaneous assembly of MSRs, analogous to the random assembly of thrown matchsticks, results in the formation of 3D interparticle spaces into which host cells can be recruited and educated by the therapeutics delivered with the MSRs. Educated cells can then emigrate from the structure to interact with other immune cells. b | In another approach, a microneedle-based transcutaneous platform loaded with self-assembled immunotherapeutic nanocarriers was used. Nanoparticle-mediated encapsulation and release of the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-MT and an anti-programmed cell death 1 (PD-1) antibody from self-assembled nanoparticles are mediated through a multistep process. First, the 1-MT is conjugated to hyaluronan (HA), then this conjugate self-assembles around the anti-PD-1 antibody to form a nanoparticle for delivery. Once it has been delivered, the nanoparticle is dissociated by hyaluronidase (HAase), resulting in release of the drugs into the tumour microenvironment. These therapeutics can be delivered using microneedles as shown. c | A subcutaneously delivered porous biomaterial scaffold that releases a chemoattractant recruits naive dendritic cells into its void space. Scaffold-resident dendritic cells are exposed to tumour antigens and adjuvants, resulting in increased presentation of peptides on major histocompatibility complex (MHC)-peptide complexes and phenotypic maturation. Mature dendritic cells traffic out of the scaffold to lymph nodes, where they can stimulate antitumour immunity.
Although this strategy avoids the risks associated with surgical implantation, the biodegradation and safety of injected silica rods and PEI will need to be investigated further in future studies.
Injectable hydrogels for combination immunotherapychemotherapy. As a biodegradable alternative to silica, injectable in situ forming hydrogels have been designed to locally deliver combinations of immunotherapies and chemotherapies 201 . Combination approaches could be particularly useful for treating patients with low-immunogenicity tumours that respond poorly to checkpoint inhibitors or patients who have immunerelated side effects 201 . In one study, injectable poly(vinyl alcohol) (PVA) hydrogel networks were designed to be responsive to reactive oxygen species, which are present at high levels in the tumour microenvironment 202 . Upon injection in a low-immunogenicity murine model of breast cancer, the hydrogel degraded and first released the chemotherapeutic gemcitabine to kill cancer cells and promote an immunogenic tumour phenotype and then released an anti-PD-L1 antibody to stimulate antitumour immunity 201 . Local injection of hydrogels also inhibited post-surgical tumour recurrence in a murine model of melanoma, extending survival compared with local or systemic injections of free gemcitabine and an anti-PD-L1 antibody 201 . Because injectable hydrogels can locally deliver both chemotherapy drugs and immunotherapies such as checkpoint inhibitors, we anticipate that this strategy can improve the therapeutic outcome in cancers with low immunogenicity. Furthermore, this technique may avoid the toxic side effects associated with systemically administered checkpoint inhibitors or chemotherapies. In the future, these injectable hydrogels could be further engineered to enable high-precision control over the release kinetics of the loaded therapies for sustained treatment regimens.
Transdermal delivery. Although systemically administered checkpoint inhibitors targeting CTLA4 or PD-1 have been approved for the treatment of melanoma, a substantial proportion of patients are not responsive to treatment (for example, the objective response rate to the anti-PD-1 mAb nivolumab in metastatic melanoma is ~40%) 203 . Minimally invasive transdermal delivery systems have been designed to enable sustained release of anti-PD-1 mAbs in a controlled manner directly at the disease site, thereby minimizing the required dose 38, 143, 204 ( fIg. 4) . These delivery systems consist of a degradable microneedle patch 205 , which can painlessly penetrate skin to reach the immune cell-rich epidermis to deliver immunotherapeutics 38, 143 . Microneedles typically consist of a biodegradable polymer, such as hyaluronic acid, and are loaded with pH-sensitive nanoparticles that contain anti-PD-1 (ref.
143
). In the mildly acidic tumour microenvironment, pH-sensitive nanoparticles release anti-PD-1 to locally activate the immune system to attack cancer cells. In a mouse model of melanoma, a single administration of the microneedle-based patch induced a robust immune response compared with nonpH-responsive microneedles or intratumoural injection of free anti-PD-1 antibodies, achieving 40% survival after 40 days, whereas other treatment groups died after 30 days 143 . The microneedle delivery system is highly modular, as nanoparticles within the microneedles can be integrated with other immune-modulating drugs such as 1-methyl-dl-tryptophan (1-MT), an inhibitor of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) 38 . Combined transdermal delivery of anti-PD-1 and 1-MT via pH-sensitive microneedles resulted in 70% survival after 40 days in a murine model of melanoma, which was a substantial improvement over control groups 38 . Microneedle patches have also been integrated with the natural biological pigment melanin to improve immunotherapy delivery 204 . In this study, microneedle patches were loaded with whole tumour cell lysate and melanin. When exposed to near-infrared light, the melanin generates heat, which causes the local release of inflammatory cytokines, adjuvants and other danger signals from endogenous tissue to attract and activate immune cells 204 . Microneedles loaded with melanin and tumour lysate promoted tumour antigen uptake by dendritic cells in a mouse model of melanoma and induced complete tumour rejection in 87% of treated mice exposed to near-infrared light, whereas microneedle-treated mice without near-infrared exposure died after 35 days 204 . Collectively, microneedle-based transdermal delivery systems offer a highly modular approach for local immunotherapy, exploiting both biological and remotely triggered stimuli for controlled drug release. Evaluation of the bioavailability of therapeutics within the patch, as well as the biocompatibility of the delivery system, will require further studies to assess clinical translatability.
T cell therapy delivery technologies Surface-conjugated nanoparticles for cell engineering. A major limitation of adoptive T cell therapies is that the viability and function of the transplanted cells rapidly decline after administration. Such cell-based therapies therefore require concurrent administration of adjuvant drugs to maximize the efficacy and performance of the cells 206 . However, these drugs need to be administered systemically at high dosages, leading to numerous toxic side effects 74 . To overcome these obstacles, delivery technologies consisting of nanoparticles, scaffolds or a combination of both are now being explored.
Adjuvant-loaded nanoparticles that are chemically conjugated to the surface of donor T cells as a means to stimulate transplanted cells and minimize the systemic side effects of adjuvants have been designed 207 (fIg. 5a) .
In one example, liposomes and liposome-like synthetic particles that encapsulated adjuvants were stably functionalized to the surface of T cells via maleimidebased conjugation 207 . In a metastatic murine model of melanoma, nanoparticle-functionalized T cells that contained adjuvant substantially boosted T cell production compared with the systemic administration of the free adjuvant 207 . All mice treated with nanoparticlefunctionalized T cells achieved complete tumour clearance, whereas treatment with non-functionalized T cells plus free adjuvant achieved only modest survival improvements over untreated mice 207 . This approach www.nature.com/nrd is highly modular and has been adapted to deliver a range of immune-stimulating drugs. In other studies, nanoparticle-functionalized T cells have been utilized for synapse-directed delivery of immunomodulators to improve adoptive T cell therapy in a murine model of prostate cancer 208 , as well as to improve the delivery of chemotherapeutics with unfavourable pharmacokinetics to disseminated tumours in a mouse model of lymphoma 209 . Immune-stimulating drug delivery systems conjugated directly to the surface of T cells can reduce the toxic side effects of systemic administration and simultaneously exploit the ability of T cells to migrate into tumours, which improves drug penetration at disease sites. One challenge is how quickly T cells can proliferate in vivo in large animal models and whether in vivo T cell proliferation is a more appropriate measurement than in vitro expansion. The liposomal and multilamellar lipid nanoparticles used in these studies also have a short release profile and, thus, investigation into polymeric platforms that achieve long-term release of adjuvants could increase T cell proliferation in vivo.
In situ T cell engineering via DNA nanocarriers. In an effort to overcome the elaborate procedures and high costs required to generate large numbers of adoptive T cells in vitro 210 , delivery technologies to engineer T cells in situ are now being developed 211 (fIg. 5b) . As an alternative to in vitro genetic engineering, a nanoparticle platform was designed to reprogramme T cells in the circulation with leukaemia-recognizing CAR genes 211 . The platform was designed to target and enter T cells in the bloodstream of the mouse and then deliver CAR genes into the T cell nucleus 211 . Poly(β-amino ester) (PBAE)-based nanoparticles were utilized to deliver DNA cargo into the nucleus of T cells 212 and were further functionalized with peptides containing microtubule-associated sequences and nuclear localization signals to facilitate nuclear import of CAR-encoding DNA 211 . Nanoparticles were coated with polyglutamic acid to shield the positive charge of the PBAE and functionalized with antibody fragments targeting CD3 on T cells to enable receptormediated endocytosis 211 . Nanoparticles administered systemically to mice bound primarily to circulating T cells, with minimal binding to other circulating cells NAtuRe Reviews | DRUg DiSCoveRY in blood 211 . In a mouse model of B cell lymphoblastic leukaemia, nanoparticles administered systemically achieved sufficient CAR expression in T cells to eradicate tumours in seven out of ten mice, whereas the remaining three mice survived for an average of 58 days longer than controls 211 . Importantly, the efficacy of this platform was comparable to conventional adoptive T cell therapy, as no substantial differences in animal survival were observed between adoptive T cell therapy and the nanoparticle-based approach 211 . Collectively, engineering T cells in situ using nanoparticles could provide a practical and low-cost means of engineering CAR T cells directly in the patient to treat cancer. However, ex vivo engineering of CAR T cells avoids the potential off-target effects that gene therapies have when administered systemically, and the potential toxic side effects of introducing CAR genes into nontarget cells remains unclear. Future studies will need to address whether the cost-saving benefits of programming CAR T cells in vivo will outweigh the potential safety concerns regarding unintentional gene transfer.
Biomaterial-based implants for local adoptive T cell delivery. Beyond systemic administration routes, biomaterials-based strategies have also been explored to locally deliver adoptive T cells to solid tumours 37, 213 . Although adoptive T cell therapies have yielded promising results for several types of cancers, including melanoma and haematological malignancies [214] [215] [216] , successful targeting of T cells to most solid cancers remains challenging 13 . These therapies are impaired, in part, by the inefficient migration of T cells into tumours and a lack of T cell expansion in the immunosuppressive tumour microenvironment [217] [218] [219] . Therefore, technologies that locally deliver T cells to the tumour microenvironment and increase their proliferation could provide a means to treat inoperable solid tumours via immunotherapy.
Polymeric scaffolds have recently been investigated for the local delivery of T cells to the tumour microenvironment 37, 213 . In addition to localizing T cells at or near tumour sites, polymeric scaffolds are advantageous because they can act as reservoirs from which propagating T cells are released as the material degrades 37 . Peptides that bind to T cell adhesion receptors can also be chemically conjugated to polymer scaffolds, thus mimicking the collagen fibres to which T cells normally bind, which enables their migration out of the scaffold and into tumours 37 . In addition to adhesion peptides, scaffolds can also be functionalized with various immune-stimulating drugs, such as adjuvants, as a means to enable both local T cell-mediated tumour destruction and systemic antitumour immunity 213 . In a recent study, polymerized alginate scaffolds functionalized with a collagen-mimetic peptide were designed to deliver both T cells and silica microparticles to stimulate and promote the proliferation of T cells 37 . The silica microparticles embedded within the scaffold encapsulated a T cell-stimulating IL-15 superagonist, and they were coated with a lipid membrane that was functionalized with antibodies to promote receptormediated T cell proliferation 37 . In a murine model of breast cancer resection, local delivery of scaffolds to resection sites prevented tumour relapse entirely compared with systemically administered T cells, which yielded no improvement over untreated controls 37 . In an aggressive, immunosuppressive mouse model of ovarian cancer, local delivery of T cell implants eradicated six out of ten tumours and induced substantial regression in the others, whereas systemically or locally administered T cells had little curative effect 37 . In another study, T cellloaded scaffolds were functionalized with STING agonists as a means to trigger systemic immunity, thereby stimulating immune responses to eliminate tumour cells in a murine model of pancreatic cancer that is not recognized by adoptively transferred T cells 213 . Overall, biomaterial-mediated local T cell delivery approaches could improve the efficiency of adoptive T cell therapies for treating inoperable solid tumours by overcoming local immunosuppressive barriers. Promoting the expansion of T cells within polymeric scaffolds removes the need to expand T cells in vitro for systemically administered therapies and minimizes the need for systemically administered conditioning regimens that are associated with toxic side effects. The usefulness of these therapies depends on how quickly T cells can be generated in tumours in vivo using this approach relative to the time it takes to expand T cells ex vivo. Furthermore, it remains to be elucidated whether this approach, designed to locally target tumours, can eliminate distant metastases in advanced stages of cancer. . 5c) . Compared with cell-based approaches, aAPCs are simple to produce and can be stably stored and functionalized with a variety of antigens and surface ligands for tuneable immunotherapy. aAPCs have conventionally consisted of cellular scale (2-10 μm) spherical particles predominantly comprising lipids, magnetic molecules or polymers [220] [221] [222] . Although such aAPCs can activate T cells in vitro, the in vivo activation of T cells using this approach remains challenging because of the poor bioavailability and the large size of cellular scale aAPCs. To enable in vivo delivery, nanoscale aAPCs have recently been designed 221, 222 . In one example, biodegradable PLGA nanoparticles were fabricated using a film stretching technique to create nanoellipsoidal aAPCs, which had a surface area that was large enough to increase receptor binding for T cell activation but was still ideal in size for in vivo delivery 221, 222 . These aAPCs were functionalized with an MHC class I immunoglobulin dimer to enable T cell recognition by APCs and provide antigen-specificity along with the co-stimulatory anti-CD28 signal that is required for T cell activation 221 . Compared with spherical nanoaAPCs, ellipsoidal nano-aAPCs experienced reduced macrophage uptake, improved T cell stimulation and had superior pharmacokinetics in vivo 221 . Interestingly, a spherical microparticle version of this particle has also been developed to treat melanoma: PLGA-based aAPCs functionalized with an MHC immunoglobulin G (IgG) www.nature.com/nrd dimer and an anti-CD28 antibody have been delivered in combination with an anti-PD-1 checkpoint inhibitor 222 . Collectively, synthetic aAPC delivery systems offer a potential alternative to conventional adoptive T cell therapy by simultaneously presenting multiple signals on the surface of synthetic particles to activate T cells in vivo. Future iterations of these systems should assess the role of other physicochemical properties, such as particle rigidity and lipid membrane fluidity, to further optimize aAPC-T cell interactions.
Clinical translation
A range of approaches to overcome biological barriers that hinder the broad implementation of cancer immunotherapy have been discussed in this article. These technologies present several challenges and opportunities for clinical translation. First, the choice of animal models used to evaluate these platforms greatly affects the translatability from mice to humans. For example, subcutaneous implantation of immortalized cell lines, although fairly simple to implement, is not as physiologically relevant as other tumour models such as patientderived xenograft (PDX) models and GEM models, which more closely replicate human disease 223 . However, the PDX model still requires immunocompromised animals, making it challenging to translate immunotherapy results from these models to humans with intact immune systems 223 . Alternatively, in GEM models, immunocompetent mice are engineered to spontaneously develop diseases that are directly relevant to human disease 223 . The GEMs can be used to evaluate immunotherapies, but experiments can be challenging to design and control owing to the spontaneity of disease formation 223 . For more control over disease progression, tumours from GEMs can be harvested and implanted into healthy immunocompetent mice to form syngeneic GEM models, which are strong candidates for investigating metastatic disease from a single tumour source but are not as relevant to human disease as true GEM models because the tumours are implanted 223 . It is also important to note that the immune system in immunocompetent mice still has several key differences to that of humans. For example, healthy mice have a substantially higher percentage of lymphocytes than humans do, and mouse and human T cells have different expression levels and functions of cytokine receptors and co-stimulatory molecules 224 . The critical advantages and disadvantages of each mouse model, and the key differences in immune activity between animal models and humans, underscore the importance of evaluating therapies in various animal models as part of the FDA approval process 225, 226 .
Choosing the correct preclinical model is critical, as is designing delivery technologies that can feasibly be translated to patients. Some essential design criteria for clinical translation include stability of the therapy, scalability, and production cost and complexity 227 . Furthermore, the choice of materials affects the timeline for clinical translation. For example, developing systems that use FDA-approved materials are likely to get into the clinic faster than more complex, unapproved materials. This is particularly useful for lipid-based and polymer-based materials, as there are several already approved by the FDA that can be engineered as platforms for drug delivery 228, 229 . We previously discussed an interesting application that uses FDA-approved lipids to deliver mRNA to dendritic cells 156 . This technology is currently being evaluated in clinical trials of melanoma (NCT02410733). A challenge in this strategy, however, is that no mRNA-based drug is currently approved by the FDA, so this therapy may take longer to reach the clinic. Excitingly, Alnylam Pharmaceuticals recently acquired FDA approval for their lipid-siRNA complex 135 , which may set a precedence for other RNA delivery platforms for cancer therapy. Additionally, an injectable scaffold for delivering a cancer vaccine, termed WDVAX, has been licensed to Novartis and is being evaluated in clinical trials (NCT01753089) 191 . Importantly, these scaffolds comprise proteins loaded into PLGA, which is already approved by the FDA for a variety of applications 230 . The recent efforts of Novartis and Alnylam, along with many other pharmaceutical and biotechnology companies, are setting the foundations for the delivery of new immunotherapies that require novel delivery technologies for successful cancer treatment.
Conclusions and future directions
Major challenges remain before immunotherapeutics can be administered to a broad range of patients; innovation in drug delivery technologies could address many of these. Although immunotherapy has been extensively studied and broadly implemented in haematological cancers and melanoma, targeting solid tumours with currently available immunotherapies has not been achieved. The delivery of immune cells to solid tumours could be improved through a better understanding of immune cell transport into solid tissues. For example, CAR T cells have been shown to penetrate the blood-brain barrier 128, 231 . It is speculated that this is an effect of increased permeability of the blood-brain barrier in patients with certain diseases, although the precise mechanism by which this occurs remains under investigation 231 . New strategies to engineer T cells to express CARs, such as the use of CRISPR-Cas9 for multiplexed genome editing 232, 233 , could further improve our fundamental understanding of T cell delivery to target organs.
Targeting immune cells to solid tumours by cell transfer or vaccination is difficult because of the potentially immunosuppressive tumour microenvironment, high interstitial fluid pressure, compressed vasculature and dense fibrotic tissue surrounding solid tumours that hinders T cell infiltration. Future approaches that target both the immune system and the tumour microenvironment could lead to more effective immunotherapies. For example, the mechanism by which angiotensin inhibitors -which reduce extracellular matrix stiffening and increase overall survival of patients with pancreatic cancer -alter the tumour microenvironment was evaluated in patients with nonmetastatic pancreatic cancer 234 . Specifically, treatment with angiotensin inhibitors normalized the extracellular matrix, reduced expression of genes involved in pancreatic cancer, progression and increased expression of genes involved in T cell and APC activity, indicating that angiotensin inhibitors may stimulate the immune
Patient-derived xenograft (PDX) models
Cancer models in which patient-derived tumour tissue or cells are implanted into immunocompromised mice.
system to recognize pancreatic cancer 234 . Given that the angiotensin inhibitor losartan is being used in patients with pancreatic cancer in a phase II clinical trial (NCT01821729) 235 and has been shown to improve therapeutic delivery to a range of solid tumour types 236 , angiotensin inhibitors could play a future role in priming the tumour microenvironment for immunotherapy in a range of cancers. Other undiscovered drug targets in the tumour microenvironment could spur novel delivery strategies to target solid tumours.
Beyond the microenvironment, the innate ability of other blood cells in circulation to respond to pathological conditions can also be exploited to deliver immunotherapy. Macrophages, which readily invade and accumulate within solid tissues in numerous inflammatory diseases and solid tumours, could overcome the physical barriers faced by T cells 237, 238 . For example, macrophages were recently engineered to directly attack tumour cells in vivo by inhibiting SHP substrate 1 (also known as SIRPα), which prevents macrophages from attacking CD47-expressing tumour cells, using blocking antibodies 237 . In a mouse model of lung cancer, systemically administered SIRPα-inhibited macrophages specifically accumulated within tumours and induced regression for 1-2 weeks with minimal toxicity 237 . SIRPα-inhibited macrophages differentiate into tumourassociated macrophages within a week of administration and, thus, further research investigating the effects of repeated administration on tumour regression and toxicity is required 237 . Future work should also investigate new delivery technologies to expand and engineer cell therapies ex vivo. Microfluidics-based technologies have recently been developed to improve and speed up the ex vivo intracellular delivery of macromolecules to immune cells 239, 240 . Such vector-free delivery systems consist of cells that undergo rapid mechanical deformation as they pass through a constriction point within a microfluidic channel 241 . This deformation transiently disrupts the membrane of immune cells, enabling uptake of macromolecular cargo present in the buffer. This technology has been used to rapidly (~1 million cells per second) deliver a range of nucleic acids and macromolecules to immune cells, including T cells, B cells, dendritic cells and macrophages 239, 240 . Such a delivery strategy could overcome the challenges faced by electroporation-based and vector-based delivery of nucleic acids to immune cells ex vivo 242 . Although this technology is still in preclinical development, a spinout company based on this technology, SQZ Biotech (see Related links), has partnered with Roche to rapidly engineer APCs for immunotherapy.
In addition to improving delivery, biomaterials should also be designed to improve the ex vivo expansion of T cells [243] [244] [245] , which currently leads to suboptimal T cell expansion rates and products 246 . Utilizing similar scaffolds for programming dendritic cells in situ 185 , recent work has investigated mesoporous silica microrods coated with a fluid lipid bilayer, anti-CD3 and anti-CD28 antibodies, and IL-2 to create an APC-mimetic scaffold for T cell expansion 246 . By more accurately reproducing how these signals are presented by APCs in vivo, these scaffolds promoted twofold to tenfold greater polyclonal expansion of primary mouse and human T cells than the commercial expansion beads that are typically used, with similar in vivo efficacy in a mouse model of lymphoma 246 . Improved expansion and functionality of T cells using biomaterials can potentially improve T cell delivery in future studies via increased migration into target tissues with reduced off-target effects.
Future work could implement externally or internally triggered drug delivery systems, in which therapeutic payloads or engineered immune cells can be triggered to stimulate an antitumour response on demand at target tissue sites, which would reduce off-tissue effects. Indeed, early work in this area is now exploring the use of methods that are triggered mechanically, or by pH, light or ultrasound, for remotely controlled immunotherapy [33] [34] [35] . Examples that exploit the use of clinically approved materials and modalities, such as microbubbles and ultrasound, respectively, could have a somewhat simple path to clinical translation 35 . Furthermore, given that several biomaterials and drug delivery technologies activate immunostimulatory pathways in the absence of other immune signals 247, 248 , future fundamental investigations into biomaterial-immune cell interactions will be needed to design new technologies for delivery and to actively direct immune responses. Several unanswered questions remain regarding how the physiochemical properties (size, shape, charge, hydrophobicity and chemical functionality) of biomaterials influence the activation of specific immune pathways and, on a larger scale, how these interactions alter the function of important tissues involved in immunity. Future investigation into these areas could enable new strategies to leverage the immunogenicity of biomaterials in cancer immunotherapies.
Although the field of cancer immunotherapy as a whole is advancing at a rapid pace, the design of delivery technologies for this field is still in its nascent stages. In this article, we described specific examples of novel delivery systems that could improve immunotherapy because of the engineered properties of the platforms themselves, including those for targeted and/or localized delivery, controlled release, increased stability and vaccination. Not only do many of the delivery platforms described in this Review provide a means to improve the delivery of immunotherapy, many examples also provide a means to overcome the innate heterogeneity of cancer, the importance of which we anticipate will become increasingly recognized in the coming years. For example, many systems, including nanoparticles, scaffolds, hydrogels and cells, can be loaded with multiple therapeutic agents that are chosen on the basis of targets identified in patient biopsy samples. This personalized therapeutic approach would enable more comprehensive and potentially curative approaches to cancer immunotherapy. Thus, the lines of drug delivery research described here, at both the fundamental and applied levels, will prove essential in contributing to future innovations for broadly implementing cancer immunotherapy.
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